JASPER THERAPEUTICS, INC. (JSPR) Current Ratio
- Current ratio · latest quarter: Value 1.47×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.47× | Current assets / current liabilities. $11.57M ÷ $7.84M ≈ 1.47× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 11.57M USD | Assets, Current |
| Current obligations | 7.84M USD | Liabilities, Current |
| Cash and equivalents | 7.31M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.78M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.57M | $7.84M | $7.31M | (m) | (m) | (m) | $2.78M | (m) | 1.47× |
| 2026-03-31 | $20.29M | $9.00M | $14.14M | (m) | (m) | (m) | $2.44M | (m) | 2.26× |
| 2025-12-31 | $34.65M | $13.20M | $28.69M | (m) | (m) | (m) | $6.22M | (m) | 2.62× |
| 2025-09-30 | $54.56M | $21.04M | $50.90M | (m) | (m) | (m) | $9.17M | (m) | 2.59× |
| 2025-06-30 | $42.97M | $20.50M | $39.51M | (m) | (m) | (m) | $8.03M | (m) | 2.10× |
| 2025-03-31 | $53.17M | $12.33M | $48.80M | (m) | (m) | (m) | $3.00M | (m) | 4.31× |
| 2024-12-31 | $75.81M | $15.24M | $71.64M | (m) | (m) | (m) | $4.03M | (m) | 4.98× |
| 2024-09-30 | $94.81M | $12.46M | $92.50M | (m) | (m) | (m) | $3.09M | (m) | 7.61× |
| 2024-06-30 | $108.68M | $10.07M | $106.82M | (m) | (m) | (m) | $2.96M | (m) | 10.79× |
| 2024-03-31 | $120.31M | $8.92M | $118.47M | (m) | (m) | (m) | $2.39M | (m) | 13.49× |
| 2023-12-31 | $88.94M | $12.37M | $86.89M | (m) | (m) | (m) | $4.15M | (m) | 7.19× |
| 2023-09-30 | $105.22M | $11.91M | $103.87M | $3.40M | (m) | (m) | $3.26M | (m) | 8.84× |
| 2023-06-30 | $118.57M | $8.97M | $115.81M | $3.20M | (m) | (m) | $1.58M | (m) | 13.22× |
| 2023-03-31 | $132.51M | $7.89M | $129.40M | (m) | (m) | (m) | $3.85M | (m) | 16.79× |
| 2022-12-31 | $41.73M | $7.07M | $38.25M | (m) | (m) | (m) | $1.77M | (m) | 5.91× |
| 2022-09-30 | $52.41M | $7.42M | $50.95M | (m) | (m) | (m) | $3.12M | (m) | 7.06× |
| 2022-06-30 | $63.29M | $6.62M | $60.81M | (m) | (m) | (m) | $3.00M | (m) | 9.56× |
| 2022-03-31 | $73.80M | $5.97M | $70.40M | (m) | (m) | (m) | $1.47M | (m) | 12.36× |
| 2021-12-31 | $87.83M | $8.02M | $84.70M | (m) | (m) | (m) | $3.92M | (m) | 10.95× |
| 2021-09-30 | $102.41M | $9.16M | $100.91M | (m) | (m) | (m) | $2.25M | (m) | 11.18× |
| 2021-06-30 | $422.93K | $328.93K | $309.73K | (m) | (m) | (m) | (m) | (m) | 1.29× |
| 2021-03-31 | $756.80K | $180.77K | $590.61K | (m) | (m) | (m) | (m) | (m) | 4.19× |
| 2020-12-31 | $20.68M | $4.01M | $19.84M | (m) | (m) | (m) | $1.42M | (m) | 5.16× |
| 2020-09-30 | $963.51K | $180.35K | $757.52K | (m) | (m) | (m) | (m) | (m) | 5.34× |
| 2020-06-30 | $1.18M | $258.27K | $914.25K | (m) | (m) | (m) | (m) | (m) | 4.57× |
| 2020-03-31 | $1.39M | $170.95K | $1.06M | (m) | (m) | (m) | (m) | (m) | 8.13× |
| 2019-12-31 | $1.54M | $111.36K | $1.21M | (m) | (m) | (m) | (m) | (m) | 13.82× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |